Literature DB >> 11923604

TP53 genotype but not p53 immunohistochemical result predicts response to preoperative short-term radiotherapy in rectal cancer.

Daniela Kandioler1, Ronald Zwrtek, Carmen Ludwig, Elisabeth Janschek, Meinhard Ploner, Friedrich Hofbauer, Irene Kührer, Sonja Kappel, Friedrich Wrba, Manfred Horvath, Josef Karner, Karl Renner, Michael Bergmann, Judith Karner-Hanusch, Richard Pötter, Raimund Jakesz, Bela Teleky, Friedrich Herbst.   

Abstract

OBJECTIVE: To evaluate and compare the predictive power of p53 gene analysis versus p53 immunohistochemical staining in terms of response to preoperative short-term radiotherapy using 25 Gy in operable rectal cancer. SUMMARY BACKGROUND DATA: Recent studies show that p53 may be a determinant of radiosensitivity being required for induction of apoptosis in case of radiation-induced DNA damage.
METHODS: Preirradiation biopsy samples of 64 patients with rectal carcinoma were analyzed. Genetic alterations of the p53 gene were detected by complete direct sequencing of exons 2 to 10. Expression of the nuclear phosphoprotein p53 was assessed by immunohistochemical staining. Results were correlated with histopathology of resected specimens and follow-up data, respectively.
RESULTS: Mutations of the p53 gene were present in 45% of tumors. Patients with a normal p53 gene had a significant survival advantage. Comparing pre- and postradiotherapy T category, a reduction was seen in patients with normal p53 genotype only. A mutant p53 genotype was highly specific in indicating stable disease concerning T category after irradiation. Protein overexpression was detected in 61%. Overexpression of the p53 protein was not related to survival or response. The concordance between immunohistochemistry and sequencing was only 0.51.
CONCLUSIONS: The authors show that downstaging after short-term radiation may occur but is seen in tumors with normal p53 gene only. Moreover, p53 genotype but not p53 immunohistochemistry is predictive for response to preoperative short-term radiotherapy and patient survival.

Entities:  

Mesh:

Year:  2002        PMID: 11923604      PMCID: PMC1422463          DOI: 10.1097/00000658-200204000-00006

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  27 in total

Review 1.  Overexpression of p53 protein does not predict local-regional control or survival in patients with early-stage squamous cell carcinoma of the glottic larynx treated with radiotherapy.

Authors:  H H Pai; L Rochon; B Clark; M Black; G Shenouda
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-04-01       Impact factor: 7.038

2.  Peritumoral tissue reaction at transrectal US as a possible cause of overstaging in rectal cancer: histopathologic correlation.

Authors:  A G Maier; P P Barton; N R Neuhold; F Herbst; B K Teleky; G L Lechner
Journal:  Radiology       Date:  1997-06       Impact factor: 11.105

3.  Is p53 a protein that predicts the response to chemotherapy in node negative breast cancer?

Authors:  A Degeorges; A de Roquancourt; J M Extra; M Espie; E Bourstyn; P de Cremoux; T Soussi; M Marty
Journal:  Breast Cancer Res Treat       Date:  1998-01       Impact factor: 4.872

4.  Role of p53 and p21/WAF1 detection in patient selection for preoperative radiotherapy in rectal cancer patients.

Authors:  C G Fu; O Tominaga; H Nagawa; M E Nita; T Masaki; G Ishimaru; Y Higuchi; T Tsuruo; T Muto
Journal:  Dis Colon Rectum       Date:  1998-01       Impact factor: 4.585

5.  Five fractions of preoperative radiotherapy for selected cases of rectal carcinoma: long-term tumor control and tolerance to treatment.

Authors:  R J Myerson; D Genovesi; M A Lockett; E Birnbaum; J Fleshman; R Fry; I Kodner; J Menteer; J Picus; T Read; B Walz
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-02-01       Impact factor: 7.038

Review 6.  Critical issues in the evolving management of rectal cancer.

Authors:  M Mohiuddin; M M Ahmed
Journal:  Semin Oncol       Date:  1997-12       Impact factor: 4.929

7.  Long-term results of preoperative radiation therapy alone for stage T3 and T4 rectal cancer.

Authors:  N R Ahmad; D Nagle
Journal:  Br J Surg       Date:  1997-10       Impact factor: 6.939

8.  p53 immunoreactivity and single-strand conformational polymorphism analysis often fail to predict p53 mutational status.

Authors:  D M Tolbert; A E Noffsinger; M A Miller; G W DeVoe; G N Stemmermann; J S Macdonald; C M Fenoglio-Preiser
Journal:  Mod Pathol       Date:  1999-01       Impact factor: 7.842

9.  Apoptosis, proliferation, bax, bcl-2 and p53 status prior to and after preoperative radiochemotherapy for locally advanced rectal cancer.

Authors:  A Tannapfel; S Nüsslein; R Fietkau; A Katalinic; F Köckerling; C Wittekind
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-06-01       Impact factor: 7.038

10.  p53 mutation, but not p53 overexpression, correlates with survival in head and neck squamous cell carcinoma.

Authors:  H Mineta; A Borg; M Dictor; P Wahlberg; J Akervall; J Wennerberg
Journal:  Br J Cancer       Date:  1998-10       Impact factor: 7.640

View more
  19 in total

1.  CoA Synthase (COASY) Mediates Radiation Resistance via PI3K Signaling in Rectal Cancer.

Authors:  Sylvain Ferrandon; Jennifer DeVecchio; Leonardo Duraes; Hanumant Chouhan; Georgios Karagkounis; Jacqueline Davenport; Matthew Orloff; David Liska; Matthew F Kalady
Journal:  Cancer Res       Date:  2019-11-08       Impact factor: 12.701

2.  Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer.

Authors:  Julio Garcia-Aguilar; Zhenbin Chen; David D Smith; Wenyan Li; Robert D Madoff; Peter Cataldo; Jorge Marcet; Carlos Pastor
Journal:  Ann Surg       Date:  2011-09       Impact factor: 12.969

3.  Synergistic cytotoxic effects of recombinant human adenovirus p53 and radiation at various time points in A549 lung adenocarcinoma cells.

Authors:  Jie-Tao Ma; Cheng-Bo Han; Jian-Zhu Zhao; Wei Jing; Yang Zhou; LE-Tian Huang; Hua-Wei Zou
Journal:  Oncol Lett       Date:  2012-06-08       Impact factor: 2.967

4.  Immunohistochemical study of PUMA, c-Myb and p53 expression in the benign and malignant lesions of gallbladder and their clinicopathological significances.

Authors:  Guo-shun Shu; Fang Lv; Zhu-lin Yang; Xiong-ying Miao
Journal:  Int J Clin Oncol       Date:  2012-06-21       Impact factor: 3.402

5.  Mutation in BRAF and SMAD4 associated with resistance to neoadjuvant chemoradiation therapy in locally advanced rectal cancer.

Authors:  Dan Jiang; Xin Wang; Yajian Wang; Dana Philips; Wenjian Meng; Moli Xiong; Junyi Zhao; Linyong Sun; Du He; Kun Li
Journal:  Virchows Arch       Date:  2019-05-06       Impact factor: 4.064

6.  p27 expression in post-treatment rectal cancer: a potential novel approach for predicting residual nodal disease.

Authors:  Tobias Leibold; Vanessa W Hui; Jinru Shia; Jeannine A Ruby; Elyn R Riedel; José G Guillem
Journal:  Am J Surg       Date:  2014-04-13       Impact factor: 2.565

7.  Adjuvant therapy for rectal cancer.

Authors:  Smitha S Krishnamurthi; Yuji Seo; Timothy J Kinsella
Journal:  Clin Colon Rectal Surg       Date:  2007-08

8.  Survivin, p53, and Ki-67 as predictors of histopathologic response in locally advanced rectal cancer treated with preoperative chemoradiotherapy.

Authors:  Cem Terzi; Aras Emre Canda; Ozgul Sagol; Koray Atila; Devrim Sonmez; Mehmet Fuzun; Ilknur B Gorken; Ilhan Oztop; Funda Obuz
Journal:  Int J Colorectal Dis       Date:  2007-09-06       Impact factor: 2.571

9.  Immunohistochemical evaluation of cell cycle regulators: impact on predicting prognosis in stage t1 urinary bladder cancer.

Authors:  Hans Olsson; Per Hultman; Nastaran Monsef; Johan Rosell; Staffan Jahnson
Journal:  ISRN Urol       Date:  2012-12-06

10.  P53 status as a predictive biomarker for patients receiving neoadjuvant radiation-based treatment: a meta-analysis in rectal cancer.

Authors:  Min-Bin Chen; Xiao-Yang Wu; Rong Yu; Chen Li; Li-Qiang Wang; Wei Shen; Pei-Hua Lu
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.